MSH2 and prostate cancer: Additionally, MSH2, MSH6, and PMS2 [63] variants were identified in 0.4% (n = 8), 0.2% (n = 5), and 0.2% (n = 4), with 0.8% of prostate cancer patients having Lynch syndrome-associated variants overall.